Clinical trials · California
Alzheimer’s disease clinical trials in California
We’re tracking 68 recruiting alzheimer’s disease studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT07688213RecruitingPhase 2
Study of an investigational drug for early Alzheimer's disease
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
Oakland, CaliforniaAges 55–85 - NCT07167966Enrolling by invitationPhase 2
Alzheimer's tau vaccine study (AADvac1)
This trial tests a vaccine that targets tau tangles in the brain, which are linked to Alzheimer's. It is part of a larger platform study that combines different experimental treatments.
San Francisco, CaliforniaAges 50–80 - NCT06957418RecruitingPhase 2
Alzheimer's tau drug study for early stage patients
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
San Francisco, CaliforniaAges 50–80 - NCT06860828Enrolling by invitation
Football players and brain health study: DIAGNOSE CTE
This study looks at brain changes in former college and professional football players, people with memory problems, and healthy controls. It aims to learn more about chronic traumatic encephalopathy (CTE) and Alzheimer's disease.
San Francisco, CaliforniaAges 50 years+ - NCT06847321RecruitingPhase 2
Testing LHP588 for Alzheimer's linked to a mouth bacteria
This trial tests a new medication, LHP588, for people with Alzheimer's who also have a common mouth bacteria called P. gingivalis. The goal is to see if targeting this bacteria can help slow down memory loss.
Murrieta, CaliforniaAges 55–80 - NCT06597942RecruitingPhase 1/Phase 2
Brain stimulation for Alzheimer's disease
This study tests whether a new type of brain stimulation (called repetitive transcranial magnetic stimulation, or rTMS) with a larger coil can improve memory and thinking in people with mild to moderate Alzheimer's disease. It involves multiple sessions of rTMS and MRI scans.
Los Angeles, CaliforniaAges 55–100 - NCT06548191RecruitingPhase 1
Time-Restricted Eating for Alzheimer's Disease
This study tests whether a time-restricted eating schedule (eating all meals within a 10-hour window each day) can improve memory and thinking in people with early Alzheimer's disease or mild cognitive impairment. Healthy partners of people with memory problems can also join as a comparison group.
San Diego, CaliforniaAges 60 years+ - NCT06416072Enrolling by invitation
Blood marker study for people not eligible for Alzheimer's prevention trials
This study looks at blood markers in people who were part of an early Alzheimer's prevention study but did not qualify for it because their amyloid levels were too low. It aims to understand brain changes and possibly find ways to detect Alzheimer's even earlier.
San Diego, CaliforniaAges 55–80 - NCT07787169RecruitingPhase 1
Study of amyloid-targeting therapies for Alzheimer's disease
This study tests several new experimental medications that target amyloid plaques, the protein clumps linked to Alzheimer's disease. It aims to find out if these treatments are safe and well-tolerated in people with early-stage Alzheimer's and in healthy volunteers.
Anaheim, CaliforniaAges 18–85 - NCT07598370RecruitingPhase 1
Testing LY3439539 for early-stage Alzheimer's disease
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
Long Beach, CaliforniaAges 50–85 - NCT04800588Recruiting
Computer tests to study early Alzheimer’s changes
This study uses computer and touch-screen tasks to measure thinking changes in people who may be in the early, symptom-free stage of Alzheimer’s disease. It aims to understand how these brain-related changes show up on testing, which could help future detection or tracking.
Berkeley, CaliforniaAges 18–89 - NCT06647498RecruitingPhase 2/Phase 3
Study of a treatment for early-onset Alzheimer's caused by a gene change
This study tests a potential disease-modifying treatment for people who have a specific gene mutation that causes early-onset Alzheimer's disease. The goal is to see if the treatment can delay or prevent symptoms.
La Jolla, CaliforniaAges 18 years+ - NCT06052163RecruitingPhase 2
Testing bumetanide for early Alzheimer's disease
This study tests whether a water pill called bumetanide can help people with early Alzheimer's disease. It involves taking the study drug, having MRI scans, and doing memory tests to see if it slows down symptoms.
Stanford, CaliforniaAges 50–85 - NCT05552157RecruitingPhase 2/Phase 3
Study of treatments for early onset Alzheimer's caused by genetic mutations
This trial tests potential treatments for people who are at risk for or have early onset Alzheimer's disease due to a specific genetic mutation. It aims to find treatments that could slow or prevent symptoms.
La Jolla, CaliforniaAges 18 years+ - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Imperial, CaliforniaAges 50–90 - NCT07717411RecruitingPhase 3
Trontinemab for people at risk of Alzheimer's symptoms
This study tests an investigational drug, trontinemab, in people who are cognitively healthy but have a blood marker suggesting a high chance of developing Alzheimer's symptoms later. The goal is to see if the drug can delay or prevent memory loss.
Irvine, CaliforniaAges 55–80 - NCT07633470RecruitingPhase 4
Zunveyl for Alzheimer's disease symptoms and caregiver support
This study tests a medication called Zunveyl to see if it helps reduce behavioral and neuropsychiatric symptoms in people with mild-to-moderate Alzheimer's disease, and whether it reduces stress on family caregivers. You would need a confirmed Alzheimer's diagnosis supported by a blood test, and a dedicated caregiver who can attend visits and report on your symptoms.
Irvine, CaliforniaAges 50 years+ - NCT07599670RecruitingPhase 1/Phase 2
Safety study of ABBV-1758 injection for Alzheimer's disease
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
Irvine, CaliforniaAges 50–90 - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Irvine, CaliforniaAges 50–85 - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Garden Grove, CaliforniaAges 55–90 - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Long Beach, CaliforniaAges 60–85 - NCT06808984RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's disease
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Anaheim, CaliforniaAges 55–90 - NCT06657768RecruitingPhase 1
Study of LY4006895 for healthy people and those with early Alzheimer's
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
Los Alamitos, CaliforniaAges 45–85 - NCT06189963RecruitingPhase 1/Phase 2
Cell therapy trial for moderate Alzheimer's disease
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
Glendale, CaliforniaAges 40–85
Alzheimer’s disease trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting alzheimer’s disease studies listed above.
- Healthy Brain Clinic · 4 studies
- Irvine Center for Clinical Research · 3 studies
- Oakland Clinical · 3 studies
- Syrentis Clinical Research · 3 studies
- ATP Clinical Research · 2 studies
- Irvine Clinical Research · 2 studies
- Local Institution · 2 studies
- Stanford University · 2 studies
What taking part in a alzheimer’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Alzheimer’s disease trials in other states
Common questions
- Are there alzheimer’s disease clinical trials in California?
- Yes. We're currently tracking 68 recruiting alzheimer’s disease studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a alzheimer’s disease study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New alzheimer’s disease studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.